Eprex Indications/Uses

Treatment of anemia associated with chronic renal failure in adult hemodialysis, peritoneal dialysis and predialysis patients and pediatric patients on hemodialysis.
Treatment of anemia and reduction of transfusion in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
Treatment of anemia in HIV-infected patients being treated with zidovudine who have endogenous erythropoietin levels ≤ 500 mIU/mL.
To facilitate autologous blood collection within a predeposit program and decrease the risk of receiving allogeneic blood transfusions in patients with hematocrits of 33 - 39%, who are scheduled for major elective surgery and are expected to require more blood than that which can be obtained through autologous blood collection techniques in the absence of Eprex.
Eprex is indicated in adult patients with mild to moderate anemia (hemoglobin > 10 to ≤ 13 g/dL) scheduled for elective surgery with an expected moderate blood loss (2 - 4 units or 900 to 1800 mL) to reduce exposure to allogeneic blood transfusions and to facilitate erythropoietic recovery).
Eprex is indicated for the treatment of anemia (hemoglobin concentration of ≤ 10 g/dL) in adults with low- or intermediate-1-risk myelodysplastic syndromes (MDS) who have low serum erythropoietin (< 200 mU/mL).